Decent, safe work
A (97)
Screens
Advertising
Alcohol
Anti-abortion support
Cannabis
Carbon emissions intensity
Coal
Contraceptives
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Misleading communication
Music
Myanmar
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Pharma controveries
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Sudan
Sugar
Syria
Tobacco
Undermining US elections
Weapons
Impact

Cause A
Peer rank
Decent, safe work

Name Rating
Loading...
Screens
Advertising
Alcohol
Anti-abortion support
Cannabis
Carbon emissions intensity
Coal
Contraceptives
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Misleading communication
Music
Myanmar
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Opioid controversies
Oppressive governments
Pharma controveries
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Sudan
Sugar
Syria
Tobacco
Undermining US elections
Weapons
Top metrics
Sample of top metrics driving Agilent's rating for decent, safe work opportunities (A, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Agilent for decent, safe work opportunities. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Agilent for decent, safe work opportunities

...

of potential metrics used

...

unique data

...

peer-average data

4 days ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Agilent. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
A Price
$152.30
Last available end-of-day price. Full disclosure
Revenue
$6.66 billion
Market cap
$40.29 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
1999
Employees
17,700
Sector
Healthcare
Industry
Healthcare Software & Services
Peer group
Medical Laboratories and Research
Headquarters
California, United States
Share classes
A
Mission
Dedicated to innovation and contribution, trust, respect, teamwork, and uncompromising integrity. We also thrive on speed, focus, and accountability.
Description
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquar
Material causes
Ethos considers the following causes material for Agilent, based on its industry peer group Medical Laboratories and Research. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.